NEUROCRINE BIOSCIENCES ($NASDAQ:NBIX) reported their financial results for the second quarter of 2023 on June 30. Their total revenue increased by 19.7% year-over-year, reaching USD 452.7 million. Additionally, their net income rose greatly from the same period a year earlier, which was -16.9 million, to USD 95.5 million.
The company’s stock opened at $102.5 and closed at $103.4, representing a gain of 1.5% from its previous closing price of $101.9. Overall, the news of NEUROCRINE BIOSCIENCES‘ second quarter earnings was cautiously positive as the company managed to increase both its revenues and net income from the same period in the previous year. Investors reacted positively to the news as the company’s stock gained 1.5% in value from the time it opened on Tuesday to when it closed. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Neurocrine Biosciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Neurocrine Biosciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Neurocrine Biosciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Neurocrine Biosciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of NEUROCRINE BIOSCIENCES‘ wellbeing. After looking at a number of financial and business aspects, we have concluded that NEUROCRINE BIOSCIENCES is a high risk investment. In order to come to this conclusion, we took a look at the company’s income sheet, balance sheet, and non financial data. We identified three risk warnings in the data, which can be accessed by registering as a user. We hope that our analysis of NEUROCRINE BIOSCIENCES’ wellbeing will help potential investors make more informed decisions. With the right information at hand, investors can make wiser decisions on whether or not to invest in this company. More…
Risk Rating Analysis
Star Chart Analysis
The company’s main competitors are TherapeuticsMD Inc, Invion Ltd, and Evotec SE.
TherapeuticsMD Inc is a biopharmaceutical company that develops and commercializes products for patients in the United States. The company has a market cap of 63.15M as of 2022 and a return on equity of 7.51%. TherapeuticsMD Inc focuses on developing and commercializing products for the treatment of menopause, osteoporosis, and other hormone-related disorders. The company’s products include ANNOVERA, an estrogen therapy; IMVEXXY, a bio-identical 17P; and BIJUVA, a bio-identical 17P/E2 combination therapy. TherapeuticsMD Inc was founded in 2010 and is headquartered in Boca Raton, Florida.
Invion Ltd is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of inflammatory diseases. The company has a market capitalization of $70.62 million and a return on equity of -7.31%. The company’s products include INV102, which is in clinical development for the treatment of asthma and chronic obstructive pulmonary disease, and INV103, which is in preclinical development for the treatment of psoriasis.
Evotec SE is a German biotechnology company focused on drug discovery and development. It has a market cap of 3.19B as of 2022 and a return on equity of 2.04%. The company has a strong focus on neuroscience and has a number of products in clinical trials for conditions such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.
NEUROCRINE BIOSCIENCES had a successful second quarter of 2023, with total revenue increasing by 19.7% year-over-year to USD 452.7 million and net income jumping from -16.9 million to USD 95.5 million. This positive performance makes NEUROCRINE BIOSCIENCES a good investment option in the current market. The company has shown strong financial growth, and investors can expect further success in the future.